{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:39:55Z","timestamp":1791329995833,"version":"4.3.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofdiabetes.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Diabetes"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.jcjd.2013.07.062","type":"journal-article","created":{"date-parts":[[2013,9,28]],"date-time":"2013-09-28T05:54:41Z","timestamp":1380347681000},"page":"319-326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Diabetic Dyslipidemia: From Evolving Pathophysiological Insight to Emerging Therapeutic Targets"],"prefix":"10.1016","volume":"37","author":[{"given":"Dominic S.","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjd.2013.07.062_bib1","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.2337\/diabetes.52.5.1210","article-title":"NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older","volume":"52","author":"Alexander","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.jcjd.2013.07.062_bib2","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1161\/ATVBAHA.107.160192","article-title":"Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome","volume":"28","author":"Adiels","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jcjd.2013.07.062_bib3","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s11892-013-0380-1","article-title":"Is the risk and nature of CVD the same in type 1 and type 2 diabetes?","volume":"13","author":"Duca","year":"2013","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.jcjd.2013.07.062_bib4","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2337\/diacare.28.5.1051","article-title":"Awareness and treatment of dyslipidemia in young adults with type 1 diabetes","volume":"28","author":"Wadwa","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2013.07.062_bib5","first-page":"685","article-title":"Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study","volume":"30","author":"Duvillard","year":"2000","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jcjd.2013.07.062_bib6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2337\/diab.31.3.217","article-title":"Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in non-insulin-dependent diabetes mellitus","volume":"31","author":"Kissebah","year":"1982","journal-title":"Diabetes"},{"key":"10.1016\/j.jcjd.2013.07.062_bib7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cmet.2011.06.002","article-title":"Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways","volume":"14","author":"Yecies","year":"2011","journal-title":"Cell Metab"},{"key":"10.1016\/j.jcjd.2013.07.062_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/nm.3259","article-title":"Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability","author":"Pajvani","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.jcjd.2013.07.062_bib9","doi-asserted-by":"crossref","first-page":"684","DOI":"10.2174\/157016112803520864","article-title":"Mechanisms of diabetic dyslipidemia: relevance for atherogenesis","volume":"10","author":"Arca","year":"2012","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.jcjd.2013.07.062_bib10","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.bbalip.2012.02.001","article-title":"The degradation of apolipoprotein B100: multiple opportunities to regulate VLDL triglyceride production by different proteolytic pathways","volume":"1821","author":"Fisher","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jcjd.2013.07.062_bib11","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1161\/ATVBAHA.111.226100","article-title":"Triglycerides and heart disease: still a hypothesis?","volume":"31","author":"Goldberg","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"Pt 3","key":"10.1016\/j.jcjd.2013.07.062_bib12","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1042\/BST0350454","article-title":"The induction of macrophage foam cell formation by chylomicron remnants","volume":"35","author":"Botham","year":"2007","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.jcjd.2013.07.062_bib13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cca.2007.12.012","article-title":"Detection of apolipoproteins B-48 and B-100 carrying particles in lipoprotein fractions extracted from human aortic atherosclerotic plaques in sudden cardiac death cases","volume":"390","author":"Nakano","year":"2008","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jcjd.2013.07.062_bib14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1161\/ATVBAHA.109.196329","article-title":"Chylomicronemia elicits atherosclerosis in mice\u2013brief report","volume":"30","author":"Weinstein","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jcjd.2013.07.062_bib15","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.bbalip.2011.09.019","article-title":"Regulation of chylomicron production in humans","volume":"1821","author":"Xiao","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jcjd.2013.07.062_bib16","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.bbalip.2011.09.013","article-title":"Gut triglyceride production","volume":"1821","author":"Pan","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jcjd.2013.07.062_bib17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.atherosclerosis.2010.05.028","article-title":"Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus","volume":"212","author":"Schwartz","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jcjd.2013.07.062_bib18","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1161\/ATVBAHA.112.246207","article-title":"Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans","volume":"32","author":"Xiao","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jcjd.2013.07.062_bib19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2337\/db12-0202","article-title":"GLP-1 and GLP-2 as yin and yang of intestinal lipoprotein production: evidence for predominance of GLP-2-stimulated postprandial lipemia in normal and insulin-resistant states","volume":"62","author":"Hein","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.jcjd.2013.07.062_bib20","article-title":"Insulin resistance, small LDL particles, and risk for atherosclerotic disease","author":"Toth","year":"2013","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.jcjd.2013.07.062_bib21","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/11905","article-title":"Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency","volume":"22","author":"Brooks-Wilson","year":"1999","journal-title":"Nat Genet"},{"key":"10.1016\/j.jcjd.2013.07.062_bib22","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/11921","article-title":"Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1","volume":"22","author":"Rust","year":"1999","journal-title":"Nat Genet"},{"key":"10.1016\/j.jcjd.2013.07.062_bib23","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(99)07026-9","article-title":"Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux","volume":"354","author":"Marcil","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jcjd.2013.07.062_bib24","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1161\/CIRCULATIONAHA.106.621433","article-title":"Both hepatic and extrahepatic ABCA1 have discrete and essential functions in the maintenance of plasma high-density lipoprotein cholesterol levels in\u00a0vivo","volume":"114","author":"Singaraja","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jcjd.2013.07.062_bib25","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1161\/01.ATV.0000208364.22732.16","article-title":"Macrophage ATP-binding cassette transporter A1 overexpression inhibits atherosclerotic lesion progression in low-density lipoprotein receptor knockout mice","volume":"26","author":"Van Eck","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jcjd.2013.07.062_bib26","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCRESAHA.113.301086","article-title":"Deficiency of ABCA1 and ABCG1 in macrophages increases inflammation and accelerates atherosclerosis in mice","author":"Westerterp","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.jcjd.2013.07.062_bib27","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.atherosclerosis.2011.02.021","article-title":"Insulin down-regulates specific activity of ATP-binding cassette transporter A1 for high density lipoprotein biogenesis through its specific phosphorylation","volume":"216","author":"Nonomura","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jcjd.2013.07.062_bib28","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.bbalip.2011.12.012","article-title":"The role of lecithin:cholesterol acyltransferase in the modulation of cardiometabolic risks - a clinical update and emerging insights from animal models","volume":"1821","author":"Ng","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jcjd.2013.07.062_bib29","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2362.2011.02604.x","article-title":"Increased LCAT activity and hyperglycaemia decrease the antioxidative functionality of HDL","volume":"42","author":"Kappelle","year":"2012","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jcjd.2013.07.062_bib30","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1161\/ATVBAHA.113.301297","article-title":"Increased serum cholesterol esterification rates predict coronary heart disease and sudden death in a general population","volume":"33","author":"Tanaka","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jcjd.2013.07.062_bib31","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2337\/db11-1341","article-title":"Loss of both ABCA1 and ABCG1 results in increased disturbances in islet sterol homeostasis, inflammation, and impaired \u03b2-cell function","volume":"61","author":"Kruit","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.jcjd.2013.07.062_bib32","doi-asserted-by":"crossref","first-page":"292","DOI":"10.5551\/jat.E599","article-title":"Impaired insulin secretion in four Tangier disease patients with ABCA1 mutations","volume":"16","author":"Koseki","year":"2009","journal-title":"J\u00a0Atheroscler Thromb"},{"key":"10.1016\/j.jcjd.2013.07.062_bib33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11892-009-0090-x","article-title":"Cholesterol in beta-cell dysfunction: the emerging connection between HDL cholesterol and type 2 diabetes","volume":"10","author":"Brunham","year":"2010","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.jcjd.2013.07.062_bib34","doi-asserted-by":"crossref","first-page":"7636","DOI":"10.1074\/jbc.M309439200","article-title":"Hypertriglyceridemia in lecithin-cholesterol acyltransferase-deficient mice is associated with hepatic overproduction of triglycerides, increased lipogenesis, and improved glucose tolerance","volume":"279","author":"Ng","year":"2004","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jcjd.2013.07.062_bib35","doi-asserted-by":"crossref","first-page":"17809","DOI":"10.1074\/jbc.M110.180893","article-title":"Lecithin cholesterol acyltransferase null mice are protected from diet-induced obesity and insulin resistance in a gender-specific manner through multiple pathways","volume":"286","author":"Li","year":"2011","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jcjd.2013.07.062_bib36","doi-asserted-by":"crossref","first-page":"20755","DOI":"10.1074\/jbc.M112.340919","article-title":"Lecithin:cholesterol acyltransferase deficiency protects against cholesterol-induced hepatic endoplasmic reticulum stress in mice","volume":"287","author":"Hager","year":"2012","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jcjd.2013.07.062_bib37","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1900\/RDS.2012.9.82","article-title":"Dyslipidemia and diabetes: reciprocal impact of impaired lipid metabolism and Beta-cell dysfunction on micro- and macrovascular complications","volume":"9","author":"Bardini","year":"2012","journal-title":"Rev Diabet Stud"},{"key":"10.1016\/j.jcjd.2013.07.062_bib38","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s11886-012-0309-3","article-title":"Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes","volume":"14","author":"Matikainen","year":"2012","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jcjd.2013.07.062_bib39","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.2165\/11638240-000000000-00000","article-title":"Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis","volume":"72","author":"de Vries","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.jcjd.2013.07.062_bib40","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/eci.12095","article-title":"Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial","volume":"43","author":"Kei","year":"2013","journal-title":"Eur J Clin Invest"},{"issue":"Suppl 2","key":"10.1016\/j.jcjd.2013.07.062_bib41","first-page":"B49","article-title":"Lipid intervention trials in diabetes","volume":"23","author":"Steiner","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2013.07.062_bib42","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcjd.2013.07.062_bib43","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jcjd.2013.07.062_bib44","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcjd.2013.07.062_bib45","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.amjcard.2012.09.034","volume":"111","author":"Phan","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jcjd.2013.07.062_bib46","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.jacc.2012.02.021","article-title":"The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL\/High Triglycerides: Impact on Global Health Outcomes) trial: to believe or not to believe?","volume":"59","author":"Nicholls","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcjd.2013.07.062_bib47","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","article-title":"HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment","volume":"34","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcjd.2013.07.062_bib48","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1440-1681.2011.05513.x","article-title":"Inhibition of microsomal triglyceride transfer protein improves insulin sensitivity and reduces atherogenic risk in Zucker fatty rats","volume":"38","author":"Dhote","year":"2011","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.jcjd.2013.07.062_bib49","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.atherosclerosis.2012.12.026","article-title":"Rapid regression of atherosclerosis with MTP inhibitor treatment","volume":"227","author":"Hewing","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jcjd.2013.07.062_bib50","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.2174\/1381612811319170023","article-title":"Mitochondrial triglyceride transfer protein inhibition: new achievements in the treatment of dyslipidemias","volume":"19","author":"Kostapanos","year":"2013","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jcjd.2013.07.062_bib51","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1093\/eurheartj\/ehs084","article-title":"Antisense oligonucleotides for the treatment of dyslipidaemia","volume":"33","author":"Visser","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcjd.2013.07.062_bib52","doi-asserted-by":"crossref","first-page":"635472","DOI":"10.1155\/2012\/635472","article-title":"Cardiovascular benefits of GLP-1-based therapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control","volume":"2012","author":"Forst","year":"2012","journal-title":"Exp Diabetes Res"},{"key":"10.1016\/j.jcjd.2013.07.062_bib53","unstructured":"TECOS: A randomized, placebo controlled clinical trial to evaluate cardiovascular outcomes after treatment with sitagliptin in patients with type 2 diabetes mellitus and inadequate glycemic control. ClinicalTrials.gov Identifier: NCT00790205."},{"key":"10.1016\/j.jcjd.2013.07.062_bib54","unstructured":"Risk of Cardiovascular Events in Patients With Type 2 Diabetes Initiating Oral Antidiabetic Treatments. The purpose of this study is to compare the incidence of major cardiovascular events among patients with type 2 diabetes who are new initiators of Saxagliptin and those who are new initiators of oral anti-diabetic drugs (OADs) in classes other than Dipeptidyl peptidase IV (DPP4) inhibitors. ClinicalTrials.gov Identifier: NCT01086280."},{"key":"10.1016\/j.jcjd.2013.07.062_bib55","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ahj.2009.07.028","article-title":"DEFINE investigators. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib","volume":"158","author":"Cannon","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.jcjd.2013.07.062_bib56","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1172\/JCI116949","article-title":"Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein A-I deficiency in a family with analphalipoproteinemia","volume":"93","author":"Ng","year":"1994","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jcjd.2013.07.062_bib57","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/353265a0","article-title":"Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI","volume":"353","author":"Rubin","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.jcjd.2013.07.062_bib58","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1161\/CIRCRESAHA.111.300581","article-title":"Apolipoprotein AI and high-density lipoprotein have anti-inflammatory effects on adipocytes via cholesterol transporters: ATP-binding cassette A-1, ATP-binding cassette G-1, and scavenger receptor B-1","volume":"112","author":"Umemoto","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.jcjd.2013.07.062_bib59","first-page":"357","article-title":"RVX-208, a stimulator of apolipoprotein AI gene expression for the treatment of cardiovascular diseases","volume":"11","author":"McNeill","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.jcjd.2013.07.062_bib60","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","article-title":"Effect of recombinant ApoA-I Milano on\u00a0coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial","volume":"290","author":"Nissen","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jcjd.2013.07.062_bib61","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jama.297.15.jpc70004","article-title":"Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial","volume":"297","author":"Tardif","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jcjd.2013.07.062_bib62","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1161\/01.ATV.0000014804.35824.DA","article-title":"Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages","volume":"22","author":"Aiello","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jcjd.2013.07.062_bib63","doi-asserted-by":"crossref","DOI":"10.1161\/ATVBAHA.112.301110","article-title":"Liver ABCA1 Deletion in LDLrKO mice does not impair macrophage reverse cholesterol transport or exacerbate atherogenesis","author":"Bi","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jcjd.2013.07.062_bib64","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1126\/science.1189862","article-title":"MiR-33 contributes to the regulation of cholesterol homeostasis","volume":"328","author":"Rayner","year":"2010","journal-title":"Science"}],"container-title":["Canadian Journal of Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499267113009489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499267113009489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:23:11Z","timestamp":1761492191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1499267113009489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S1499267113009489"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjd.2013.07.062","relation":{},"ISSN":["1499-2671"],"issn-type":[{"value":"1499-2671","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diabetic Dyslipidemia: From Evolving Pathophysiological Insight to Emerging Therapeutic Targets","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjd.2013.07.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Canadian Diabetes Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}